GBIO
Price
$5.98
Change
-$0.00 (-0.00%)
Updated
Sep 3 closing price
Capitalization
40.28M
62 days until earnings call
INMB
Price
$1.97
Change
-$0.00 (-0.00%)
Updated
Sep 3 closing price
Capitalization
52.11M
55 days until earnings call
Interact to see
Advertisement

GBIO vs INMB

Header iconGBIO vs INMB Comparison
Open Charts GBIO vs INMBBanner chart's image
Generation Bio
Price$5.98
Change-$0.00 (-0.00%)
Volume$59.06K
Capitalization40.28M
INmune Bio
Price$1.97
Change-$0.00 (-0.00%)
Volume$711.74K
Capitalization52.11M
GBIO vs INMB Comparison Chart in %
Loading...
GBIO
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
INMB
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
GBIO vs. INMB commentary
Sep 04, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is GBIO is a Hold and INMB is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Sep 04, 2025
Stock price -- (GBIO: $5.98 vs. INMB: $1.97)
Brand notoriety: GBIO and INMB are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: GBIO: 13% vs. INMB: 23%
Market capitalization -- GBIO: $40.28M vs. INMB: $52.11M
GBIO [@Biotechnology] is valued at $40.28M. INMB’s [@Biotechnology] market capitalization is $52.11M. The market cap for tickers in the [@Biotechnology] industry ranges from $101.69B to $0. The average market capitalization across the [@Biotechnology] industry is $1.88B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

GBIO’s FA Score shows that 0 FA rating(s) are green whileINMB’s FA Score has 0 green FA rating(s).

  • GBIO’s FA Score: 0 green, 5 red.
  • INMB’s FA Score: 0 green, 5 red.
According to our system of comparison, GBIO is a better buy in the long-term than INMB.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

GBIO’s TA Score shows that 3 TA indicator(s) are bullish while INMB’s TA Score has 4 bullish TA indicator(s).

  • GBIO’s TA Score: 3 bullish, 5 bearish.
  • INMB’s TA Score: 4 bullish, 3 bearish.
According to our system of comparison, INMB is a better buy in the short-term than GBIO.

Price Growth

GBIO (@Biotechnology) experienced а -5.83% price change this week, while INMB (@Biotechnology) price change was -3.67% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +0.29%. For the same industry, the average monthly price growth was +15.06%, and the average quarterly price growth was +30.89%.

Reported Earning Dates

GBIO is expected to report earnings on Nov 05, 2025.

INMB is expected to report earnings on Oct 29, 2025.

Industries' Descriptions

@Biotechnology (+0.29% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
INMB($52.1M) has a higher market cap than GBIO($40.3M). GBIO YTD gains are higher at: -43.585 vs. INMB (-57.816). INMB has higher annual earnings (EBITDA): -39.72M vs. GBIO (-69.92M). GBIO has more cash in the bank: 141M vs. INMB (33.4M). INMB has less debt than GBIO: INMB (451K) vs GBIO (85.3M). GBIO has higher revenues than INMB: GBIO (21.2M) vs INMB (50K).
GBIOINMBGBIO / INMB
Capitalization40.3M52.1M77%
EBITDA-69.92M-39.72M176%
Gain YTD-43.585-57.81675%
P/E RatioN/AN/A-
Revenue21.2M50K42,400%
Total Cash141M33.4M422%
Total Debt85.3M451K18,914%
FUNDAMENTALS RATINGS
INMB: Fundamental Ratings
INMB
OUTLOOK RATING
1..100
85
VALUATION
overvalued / fair valued / undervalued
1..100
77
Overvalued
PROFIT vs RISK RATING
1..100
100
SMR RATING
1..100
99
PRICE GROWTH RATING
1..100
97
P/E GROWTH RATING
1..100
100
SEASONALITY SCORE
1..100
50

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
GBIOINMB
RSI
ODDS (%)
Bearish Trend 1 day ago
84%
Bullish Trend 1 day ago
90%
Stochastic
ODDS (%)
Bullish Trend 1 day ago
88%
Bullish Trend 1 day ago
83%
Momentum
ODDS (%)
Bearish Trend 1 day ago
86%
Bearish Trend 1 day ago
82%
MACD
ODDS (%)
Bearish Trend 1 day ago
89%
N/A
TrendWeek
ODDS (%)
Bearish Trend 1 day ago
89%
Bearish Trend 1 day ago
88%
TrendMonth
ODDS (%)
Bullish Trend 1 day ago
84%
Bearish Trend 1 day ago
89%
Advances
ODDS (%)
Bullish Trend 9 days ago
86%
Bullish Trend 23 days ago
83%
Declines
ODDS (%)
Bearish Trend 3 days ago
90%
Bearish Trend 3 days ago
87%
BollingerBands
ODDS (%)
Bearish Trend 1 day ago
83%
Bullish Trend 1 day ago
90%
Aroon
ODDS (%)
Bullish Trend 1 day ago
77%
Bearish Trend 1 day ago
90%
View a ticker or compare two or three
Interact to see
Advertisement
GBIO
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
INMB
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
FSTR26.310.73
+2.85%
L.B. Foster Company
CWAN20.200.01
+0.05%
Clearwater Analytics Holdings
PEPG1.19-0.01
-0.83%
PepGen
AMGN283.85-3.07
-1.07%
Amgen
KRP13.74-0.19
-1.36%
Kimbell Royalty Partners LP

GBIO and

Correlation & Price change

A.I.dvisor indicates that over the last year, GBIO has been loosely correlated with CABA. These tickers have moved in lockstep 46% of the time. This A.I.-generated data suggests there is some statistical probability that if GBIO jumps, then CABA could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To GBIO
1D Price
Change %
GBIO100%
N/A
CABA - GBIO
46%
Loosely correlated
+8.28%
MGNX - GBIO
45%
Loosely correlated
+9.77%
OVID - GBIO
43%
Loosely correlated
+8.13%
SYRE - GBIO
43%
Loosely correlated
+1.08%
IDYA - GBIO
42%
Loosely correlated
+1.10%
More

INMB and

Correlation & Price change

A.I.dvisor indicates that over the last year, INMB has been loosely correlated with UNBX. These tickers have moved in lockstep 51% of the time. This A.I.-generated data suggests there is some statistical probability that if INMB jumps, then UNBX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To INMB
1D Price
Change %
INMB100%
N/A
UNBX - INMB
51%
Loosely correlated
-9.60%
OGEN - INMB
44%
Loosely correlated
+1.90%
GBIO - INMB
36%
Loosely correlated
N/A
PROK - INMB
36%
Loosely correlated
+2.61%
OVID - INMB
35%
Loosely correlated
+8.13%
More